Aljian Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Aljian Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$980K	Sell	17,011 -470	-3%	-$27K	0.18%	65
2026 Q1	$1.06M	Buy	17,481 +473	+3%	+$27.6K	0.22%	57
2025 Q4	$917K	Sell	17,008 -1,293	-7%	-$62.2K	0.18%	58
2025 Q3	$825K	Sell	18,301 -830	-4%	-$38.8K	0.17%	65
2025 Q2	$886K	Sell	19,131 -1,735	-8%	-$85.2K	0.19%	62
2025 Q1	$1.27M	Buy	20,866 +4,745	+29%	+$277K	0.3%	42
2024 Q4	$912K	Buy	16,121 +1,041	+7%	+$58.2K	0.2%	53
2024 Q3	$780K	Buy	+15,080	New	+$707K	0.18%	59

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Aljian Capital Management's BMY Position: Q2 2026 in Review

Aljian Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 2.7% in Q2 2026, selling an estimated $27K and leaving 17,011 shares worth $980K. The position accounts for 0.18% of the portfolio, ranked #65.

Aljian Capital Management first reported a position in BMY in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.27M in Q1 2025. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Aljian Capital Management held 17,011 shares of Bristol-Myers Squibb worth $980K as of Q2 2026.
Aljian Capital Management sold 470 Bristol-Myers Squibb shares in Q2 2026, an estimated $27K.
Bristol-Myers Squibb made up 0.18% of Aljian Capital Management's portfolio in Q2 2026, its #65 holding.
Aljian Capital Management first reported a position in Bristol-Myers Squibb in Q3 2024 and has held it in 8 quarters since.
Aljian Capital Management's Bristol-Myers Squibb position peaked at $1.27M in Q1 2025.
2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Aljian Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.